Karuna Therapeutics (KRTX) Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KRTX shares.
View KRTX analyst ratings or view top-rated stocks.

12 analysts have issued 1 year target prices for Karuna Therapeutics' shares. Their KRTX share price forecasts range from $209.00 to $323.00. On average, they anticipate the company's share price to reach $260.50 in the next twelve months. This suggests a possible upside of 62.4% from the stock's current price.
View analysts price targets for KRTX or view top-rated stocks among Wall Street analysts.

Karuna Therapeutics' stock was trading at $196.50 at the beginning of 2023. Since then, KRTX stock has decreased by 18.4% and is now trading at $160.41.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our KRTX earnings forecast.

Karuna Therapeutics, Inc. (NASDAQ:KRTX) issued its earnings results on Thursday, August, 3rd. The company reported ($2.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.76) by $0.01. The firm had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.42 million. Karuna Therapeutics had a negative trailing twelve-month return on equity of 27.13% and a negative net margin of 2,795.96%. The business's quarterly revenue was down 98.1% on a year-over-year basis. During the same period in the previous year, the business earned ($2.17) EPS.

ETFs with the largest weight of Karuna Therapeutics (NASDAQ:KRTX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ) and Vanguard Russell 2000 Growth ETF (VTWG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).

(KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX."

Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KRTX stock can currently be purchased for approximately $160.41.

Karuna Therapeutics (NASDAQ:KRTX) has a market capitalization of $6.04 billion and generates $10.64 million in revenue each year. The company earns $-276,340,000.00 in net income (profit) each year or ($10.15) on an earnings per share basis.

The company employs 210 workers across the globe.

Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The official website for the company is karunatx.com. The company can be reached via phone at (857) 449-2244 or via email at investors@karunatx.com.